åêðáéäåõóçó γ.ν.α.

ΝΟΣΟΚΟΜΕΙΑΚΑ ΧΡΟΝΙΚΑ, ΤΟΜΟΣ 71, ΣΥΜΠΛΗΡΩΜΑ, 2009
467
tion: a TRITON-TIMI 38 (TRial to Assess Improvement in
Therapeutic Outcomes by Optimizing Platelet InhibitioN
with Prasugrel–Thrombolysis In Myocardial Infarction)
analysis, J Am Coll Cardiol 2008;51:2028–2033.
45. Storey RF, Husted S, Harrington RA et al. Inhibition
of platelet aggregation by AZD6140, a reversible oral
P2Y12 receptor antagonist, compared with clopidogrel
in patients with acute coronary syndromes, J Am Coll
Cardiol 2007;50:1852–1856.
46. Cannon CP, Husted S, Harrington RA et al. Safety,
tolerability, and initial efficacy of AZD6140, the first
reversible oral adenosine diphosphate receptor antagonist,
compared with clopidogrel, in patients with
non-ST-segment elevation acute coronary syndrome:
primary results of the DISPERSE-2 trial, J Am Coll Cardiol
2007;50:1844–1851.
47. Moliterno DJ, Jennings L, Becker RC et al. Results of a
multinational randomized, double-blind, placebo-controlled
study of a novel thrombin receptor antagonist
SCH 530348 in percutaneous coronary intervention.
Paper presented at: Annual Meeting of the American
College of Cardiology; March 24, 2007; New Orleans,
LA.
48. White HD, Chew DP, Hoekstra JW et al. Safety and efficacy
of switching from either unfractionated heparin
or enoxaparin to bivalirudin in patients with non-STsegment
elevation acute coronary syndromes managed
with an invasive strategy: results from the ACUITY
(Acute Catheterization and Urgent Intervention Triage
strategY) trial, J Am Coll Cardiol 2008;51:1734–1741.
49. Gibson CM, Ten Y, Murphy SA et al. Association of prerandomization
anticoagulant switching with bleeding in
the setting of percutaneous coronary intervention (a RE-
PLACE-2 analysis), Am J Cardiol 2007;99:1687–1690.
50. Kastrati A, Neumann F-J, Mehilli J et al. and ISAR-REACT
3 Trial Investigators, Bivalirudin versus unfractionated
heparin during percutaneous coronary intervention, N
Engl J Med 2008;359:688–696.
51. Mehta SR, Granger CB, Eikelboom JW et al. Efficacy and
safety of fondaparinux versus enoxaparin in patients with
acute coronary syndromes undergoing percutaneous
coronary intervention: results from the OASIS-5 trial, J
Am Coll Cardiol 2007;50:1742–1751.
52. Fox KA, Bassand JP, Mehta SR et al. Influence of renal
function on the efficacy and safety of fondaparinux relative
to enoxaparin in non ST-segment elevation acute
coronary syndromes, Ann Intern Med 2007;147:304–
310.
53. Hirsh J, O’Donnell M, Eikelboom JW et al. Beyond unfractionated
heparin and warfarin: current and future
advances, Circulation 2007;116:552–560.
54. Chan MY, Cohen MG, Dyke CK et al. Phase 1b randomized
study of antidote-controlled modulation of
factor IXa activity in patients with stable coronary artery
disease, Circulation 2008;117:2865–2874.
55. Gilbert JC, DeFeo-Fraulini T, Hutabarat RM et al. Firstin-human
evaluation of anti von Willebrand factor
therapeutic aptamer ARC1779 in healthy volunteers,
Circulation 2007;116:2678–2686.
56. Schneider DJ, Sobel BE., Conundrums in the combined
use of anticoagulants and antiplatelet drugs, Circulation
2007;116:305–315.
57. Feit F, Voeltz MD, Attubato MJ et al. Predictors and
impact of major hemorrhage on mortality following
percutaneous coronary intervention from the REPLACE-2
Trial, Am J Cardiol 2007;100:1364–1369.
58. Ndrepepa G, Berger PB, Mehilli J et al. Periprocedural
bleeding and 1-year outcome after percutaneous coronary
interventions: appropriateness of including bleeding
as a component of a quadruple end point, J Am Coll
Cardiol 2008;51:690–697.
59. Yeh RW, Wiviott SD, Giugliano RP et al. Effect of thrombocytopenia
on outcomes following treatment with
either enoxaparin or unfractionated heparin in patients
presenting with acute coronary syndromes, Am J Cardiol
2007;100:1734–1738.
60. Alexander KP, Chen AY, Wang TY et al. Transfusion
practice and outcomes in non-ST-segment elevation
acute coronary syndromes, Am Heart J 2008;155:1047–
1053.
61. Spencer FA, Moscucci M, Granger CB et al. Does comorbidity
account for the excess mortality in patients
with major bleeding in acute myocardial infarction,
Circulation 2007;116:2793–2801.
62. Melloni C, Alexander KP, Chen AY et al. Unfractionated
heparin dosing and risk of major bleeding in non-STsegment
elevation acute coronary syndromes, Am Heart
J 2008;156:209–215.
63. Melloni C, Peterson ED, Chen AY et al. Cockcroft-Gault
versus modification of diet in renal disease: importance
of glomerular filtration rate formula for classification of
chronic kidney disease in patients with non-ST-segment
elevation acute coronary syndromes, J Am Coll Cardiol
2008;51:991–996.
64. Brieger D, Van de Werf F, Avezum A et al. Interactions
between heparins, glycoprotein IIb/IIIa antagonists, and
coronary intervention: The Global Registry of Acute Coronary
Events (GRACE), Am Heart J 2007;153:960–969.
65. Grines CL, Bonow RO, Casey Jr DE et al. Prevention of
premature discontinuation of dual antiplatelet therapy in
patients with coronary artery stents: a science advisory
from the American Heart Association, American College
of Cardiology, Society for Cardiovascular Angiography
and Interventions, American College of Surgeons, and
American Dental Association, with representation from
the American College of Physicians, J Am Coll Cardiol
2007;49:734–739.
66. Nguyen MC, Lim YL, Walton A et al. Combining warfarin
and antiplatelet therapy after coronary stenting in the
Global Registry of Acute Coronary Events: is it safe and